Article
A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.
The Journal of experimental medicine - 21 Sept 2015
Giotopoulos George, van der Weyden Louise, Osaki Hikari, Rust Alistair G, Gallipoli Paolo, Meduri Eshwar, Horton Sarah J, Chan Wai-In, Foster Donna, Prinjha Rab K, Pimanda John E, Tenen Daniel G, Vassiliou George S, Koschmieder Steffen, Adams David J, Huntly Brian J P
Abstract excerpt
The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC), are lacking. Whereas the chronic phase of CML is dependent on BCR-ABL, additional mutations are required for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.